<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Blood Test Helps Target Roche/OSI Lung Cancer Drug (Reuters)

Blood analysis good at predicting how tumours will respond;  Proteomic test useful when doctors have no tumour tissue

LONDON, April 30 (Reuters) – Testing for specific cancer protein markers in lung cancer patients’ blood helps find those more likely to respond to Tarceva, a drug sold by Roche (ROG.VX) and OSI Pharmaceuticals OSIP.O, data showed on Friday.

Read more from Reuters

Topics: biomarker, blood-based cancer test, cancer diagnostics, personalized medicine, Tarceva, lung cancer, molecular diagnostic, Non-Small Cell Lung Cancer, oncology, In the News, Pharmaceuticals, OSI, Roche